Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice

Immunology and Cell Biology

Volumn 89, Issue 5, 2011, Pages 640-649

  Patel, Tejas ^a   Patel, Vasu ^a   Singh, Rajvir ^a   Jayaraman, Sundararajan ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

epigenetics; interferon gamma gene; t regulatory cells; type 1 diabetes

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; L SELECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; ORPHAN NUCLEAR RECEPTOR; PROTEIN RORGT; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG EFFICACY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HISTONE ACETYLATION; IMMUNE SYSTEM; INFLAMMATION; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; SPLEEN; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ACETYLATION; ANIMALS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS, TYPE 1; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HYDROXAMIC ACIDS; IMMUNE SYSTEM; INFLAMMATION; INTERFERON-GAMMA; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

MUS;

EID: 79959994999     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.144     Document Type: Article

References (50)

1. Jenuwein T, Allis CD. Translating the histone code. Science 2002; 293: 1074-1080. (Pubitemid 32758077)
2. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-483. (Pubitemid 33027900)
3. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyeracetylation. Gene Expr 1996; 5: 245-253.
4. Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4 T cell responses. BMC Cancer 2003; 3: 30.
5. Takahashi I, Miyaji H, Yoshida T, Sato S, Mizukami T. Selective inhibition of IL- 2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J Antibiot 1996; 49: 453-457. (Pubitemid 26178952)
6. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-552. (Pubitemid 36228011)
7. Skov S, Rieneck K, Bovin LF, Skark K, Tomra S, Michelsen BK et al. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 2003; 101: 1430-1438. (Pubitemid 36182517)
8. Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 2001; 98: 2628-2633. (Pubitemid 32209533)
9. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299-1307. (Pubitemid 350073591)
10. Reilly CM, Thomas M, Gogal Jr R, Olgun S, Santo A, Sodhi R et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J Autoimmun 2008; 31: 123-130.
11. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006; 176: 5015-5022.
12. Choi J-H, Oh S-W, Kang M-S, Kwon HJ, Oh G-T, Kim D-Y. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005; 35: 89-96. (Pubitemid 40188276)
13. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 164: 10-21. (Pubitemid 40826758)
14. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005; 23: 115-126. (Pubitemid 41169282)
15. André I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA 1996; 93: 2260-2263. (Pubitemid 26104338)
16. Alyanakian MA, You S, Damotte D, Gouarin C, Esling A, Garcia C et al. Diversity of regulatory CD4T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci USA 2003; 100: 15806-15811. (Pubitemid 38021071)
17. Anderson JT, Cornelius JG, Jarpe AJ, Winter WE, Peck AB. Insulin-dependent diabetes in the NOD mouse model II Beta cell destruction in autoimmune diabetes is a TH 2 and not a TH1 mediated event. Autoimmunity 1993; 15: 113-122. (Pubitemid 23276006)
18. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58: 1302-1311.
19. Oikawa Y, Shimada A, Kasuga A, Morimoto J, Osaki T, Tahara H et al. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol 2003; 171: 5865-5875. (Pubitemid 37467203)
20. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I, Bedossa P et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun 1991; 4: 237-248.
21. Campbell IL, Kay TW, Oxbrow L, Harrison LC. Essential role for interferon- gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87: 739-742.
22. Trembleau S, Penna G, Gregori S, Giarratana N, Adorini L. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12- induced IFN-gamma. J Immunol 2003; 170: 5491-5501. (Pubitemid 36617837)
23. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180: 995-1004. (Pubitemid 24256612)
24. Yasuda H, Jin Z, Nakayama M, Yamada K, Kishi M, Okumachi Y et al. NO- mediated cytotoxicity contributes to multiple low-dose streptozotocin-induced diabetes but not to NOD diabetes. Diabetes Res Clin Pract 2009; 83: 200-207.
25. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 54: S114-S124.
26. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8T cells. Science 2001; 295: 338-342. (Pubitemid 34074366)
27. Yu Q, Sharma A, Oh SY, Moon HG, Hossain MZ, Salay TM et al. T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat Immunol 2009; 10: 992-999.
28. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-1133. (Pubitemid 44380299)
29. Jayaraman S, Patel T, Patel V, Ajani S, Garza R, Jayaraman A et al. Transfusion of NOD mice with allogeneic newborn blood ameliorates autoimmune diabetes and modifies the expression of selected immune response genes. J Immunol 2010; 184: 3008-3015.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real- time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
31. Calderon B, Suri A, Pan XO, Mills JC, Unanue ER. IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J Immunol 2008; 181: 6964-6974.
32. Hultgren B, Huang X, Dybdal N, Stewart TA. Genetic absence of gamma- interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45: 812-817. (Pubitemid 26166778)
33. Nicoletti F, Zaccone P, Di Marco R, Di Mauro M, Magro G, Grasso S et al. The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology 1996; 137: 5567-5575. (Pubitemid 26423125)
34. Wang B, Andre I, Gonzalez A, Katz JD, Aguet M, Benoist C et al. Interferon- gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94: 13844-13849. (Pubitemid 28009672)
35. Serreze DV, Post CM, Chapman HD, Johnson EA, Lu B, Rothman PB. Interferon-gamma receptor signaling is dispensable in the development of type 1 diabetes in NOD mice. Diabetes 2000; 49: 2007-2011.
36. Kanagawa O, Xu G, Tevaarwerk A, Vaupel BA. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J Immunol 2000; 164: 3919-3923. (Pubitemid 30169852)
37. Sobel DO, Han J, Williams J, Yoon JW, Jun HS, Ahvazi B. Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse. J Autoimmun 2002; 19: 129-137. (Pubitemid 35341862)
38. Qin H-Y, Chaturvedi P, Singh B. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol 2004; 16: 1723-1732. (Pubitemid 40003860)
39. Jain R, Tartar DM, Gregg RK, Divekar RD, Bell JJ, Lee HH et al. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008; 205: 207-218. (Pubitemid 351185727)
40. Gysemans C, Callewaert H, Overbergh L, Mathieu C. Cytokine signaling in the beta-cell: a dual role for IFNgamma. Biochem Soc Trans 2008; 36: 328-333. (Pubitemid 351839325)
41. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon- gamma: Implications for immune responses and autoimmune diseases. Immunity 2009; 31: 539-550.
42. Lugo-Villarino G, Maldonado-Lopez R, Possemato R, Penaranda C, Glimcher LH. T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci USA 2003; 100: 7749-7754. (Pubitemid 36760041)
43. Matsuda JL, George TC, Hagman J, Gapin L. Temporal dissection of T-bet functions. J Immunol 2007; 178: 3457-3465. (Pubitemid 46417610)
44. Esensten JH, Lee MR, Glimcher LH, Bluestone JA. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol 2009; 183: 75-82.
45. Melanitou E, Liu E, Miao D, Yu L, Glimcher LH, Eisenbarth G. Absence of the T-bet gene coding for the Th1-related transcription factor does not affect diabetes- associated phenotypes in Balb/c mice. Ann N Y Acad Sci 2003; 1005: 187-191. (Pubitemid 38507751)
46. Placek K, Coffre M, Maiella S, Bianchi E, Rogge L. Genetic and epigenetic networks controlling T helper 1 cell differentiation. Immunology 2009; 127: 155-162.
47. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4 and CD8T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993; 42: 44-55. (Pubitemid 23013794)
48. Wang J, Wicker LS, Santamaria P. IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. Semin Immunol 2009; 21: 363-371.
49. Haumaitre C, Lenoir O, Scharfmann R. Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors. Mol Cell Biol 2008; 28: 6373-6383.
50. Jayaraman S, Luo Y, Dorf ME. Tolerance induction in T helper (Th1) cells by thymic macrophages. J Immunol 1992; 148: 2672-2681.